Monday, March 30, 2026

Meta-analysis: GOLD-PRISm prevalence 10.60%, GOLD-RSP 12.09% in general population

Key Takeaway
Consider smoking status and comorbidities when assessing patients for preserved ratio impaired spirometry and restrictive spirometry pattern.

This systematic review and multi-level meta-analysis aimed to estimate the global prevalence and identify risk factors for preserved ratio impaired spirometry (PRISm) and restrictive spirometry pattern (RSP) in the general population. The analysis included 57 studies reporting population-based data from 31 countries, with 48 studies using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) definition included in the meta-analysis, comprising a pooled sample of 1,129,807 participants. The primary outcome was the pooled prevalence of GOLD-defined PRISm (FEV1 <80% predicted with FEV1/FVC ≥0.7) and RSP (FVC <80% predicted with FEV1/FVC ≥0.7). The results showed a pooled prevalence of GOLD-PRISm of 10.60% (19 studies; 95% CI=8.12, 13.73) and a pooled prevalence of GOLD-RSP of 12.09% (23 studies; 95% CI=7.90, 18.04). The simultaneous combined prevalence of GOLD-PRISm and RSP was 11.79% (38 studies; 95% CI=9.11, 15.12). Subgroup analysis revealed higher GOLD-PRISm prevalence in current smokers (13.37%) compared to ex-smokers (10.18%) and non-smokers (10.87%), and in populations from the Western Pacific Region (11.26%). Significant risk factors identified for GOLD-PRISm included older adults, current and former smoking, extreme body mass index, and a history of comorbidities such as asthma, diabetes, hypertension, and stroke. The study concludes by highlighting significant regional and demographic variations in prevalence and noting that key risk factors, particularly smoking and comorbidities, should be considered for early management strategies.

View Original Abstract ↓
BACKGROUND: Both preserved ratio impaired spirometry (PRISm) (defined as a forced expiratory volume in one second (FEV1) <80% of predicted, while the ratio of FEV1 to forced vital capacity (FVC) is ≥0.7) and restrictive spirometry pattern (RSP) (defined as FVC<80% of predicted, while the FEV1/FVC ratio ≥0.7) are associated with an increased risk of mortality. The global prevalence of PRISm and RSP in the general population remains unclear. Therefore, we aimed to estimate the prevalence and identify risk factors of PRISm and RSP in the general population, and to examine variations across subgroups defined by gender, smoking status, WHO regions, and World Bank income levels. METHODS: We searched three databases for studies that reported the prevalence of PRISm and RSP, and their associated risk factors in the general population. We conducted a multi-level meta-analysis, along with standard random-effects modelling, to estimate the pooled prevalence and identify key risk factors, and performed meta-regression and sensitivity analyses to assess the robustness of the results. RESULTS: We identified a total of 57 studies reporting population-based data from 31 countries. We included 48 studies for meta-analysis using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) definition, resulting in a pooled sample of 1 129 807 participants. The pooled prevalence of GOLD-PRISm was 10.60% (19 studies; 95% confidence interval (CI) = 8.12, 13.73), while the prevalence of GOLD-RSP was 12.09% (23 studies; 95% CI = 7.90, 18.04). The simultaneous combined prevalence of GOLD-PRISm and RSP was 11.79% (38 studies; 95% CI = 9.11, 15.12). Subgroup analysis showed that current smokers (13.37% vs. 10.18% in ex-smokers and 10.87% in non-smokers), and Western Pacific Region populations (11.26%) had higher prevalence rates of GOLD-PRISm. Significant risk factors for GOLD-PRISm include older adults, current and former smoking, extreme body mass index, and a history of comorbidities, such as asthma, diabetes, hypertension, and stroke. CONCLUSIONS: We provide a pooled estimate of PRISm and RSP prevalence based on studies from multiple regions, highlighting significant regional and demographic variations. Key risk factors, particularly smoking and comorbidities, should be considered when developing early management strategies.